secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2021-08-03T23:59:59+00:00
Accession:  0001558370-21-009865
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte reports Q2 2021 product revenue $696M (+17% YoY); GAAP net income $149M vs $290M prior year
--------------------------------------------------------------------------------

- Jakafi net product revenues $529M (+12% YoY); total product and royalty revenues $696M (+17%).
- Non-GAAP diluted EPS $0.80 vs $1.24 prior year; GAAP net income $149M down from $290M.
- Positive CHMP opinion for tafasitamab in relapsed/refractory DLBCL; Phase 3 vitiligo trials met endpoints.
- Updated 2021 guidance: Jakafi revenue tightened to $2,125-$2,170M; SG&A reduced to $725-$755M.
- Retifanlimab BLA received FDA complete response letter; MAA still under EMA review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000155837021009865/0001558370-21-009865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000155837021009865/incy-20210803x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-009865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer